home All News open_in_new Full Article

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat […]


today 3 w. ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Politics
attach_file Economics
attach_file Events
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics


ID: 3446538745
Add Watch Country

arrow_drop_down